### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
DMB Number:	3235-0287						
Estimated average burden							
ours per respon	se 0.5						

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

riiii or Ty	pe Response	(8)														
1. Name and Address of Reporting Person * LARSON BRENT L				N	2. Issuer Name and Ticker or Trading Symbol NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]							5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  Director X Officer (give title below)  Other (specify below)				
(Last) (First) (Middle) 5600 BLAZER PARKWAY, SUITE 200					3. Date of Earliest Transaction (Month/Day/Year) 11/02/2015								EVP,	CFO, Treas	& Sec'y	
(Street) DUBLIN, OH 43017-7550				4	4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person				
(City) (State) (Zip)					Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned									Owned		
(Instr. 3) Date			2. Transacti Date (Month/Day	y/Year) E	Execution Date, if any (Month/Day/Year)			(A) or Disp (Instr. 3, 4		Oisposed , 4 and (A) or	d of (D 5)	5. Amount of Securities  Beneficially Owned Following Reported Transaction(s)  (Instr. 3 and 4)		Following	6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common	Stock		11/02/201	5			Code S(1)	V	12,500		Price \$ 1.98 (2)	234,737			(Instr. 4) D	
indirectly.			Tab		rivative Sec		es Acquire	cont the t	tained in form dis	n this f splays of, or B	orm a a curr	re not requently validated	uired to re d OMB cor	nformation espond unl ntrol numb	ess	EC 1474 (9- 02)
				(e.g	g., puts, calls	, wa	rrants, opt	ions	, conver	tible sec	curities	s)	•			
Security	Conversion	3. Transaction Date (Month/Day/	Year) Execu	eemed ation Date th/Day/Ye	4. Transac Code ear) (Instr. 8	tion )	of	6. Date Exerc and Expiratio (Month/Day/		on Date Year)	An Un Se	Title and nount of derlying curities str. 3 and	Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownersh Form of Derivativ Security: Direct (I or Indire	Ownershi (Instr. 4) O)
					Code	V	(A) (D)	Dat Exe	e rcisable	Expirat Date	ion Tit	Amount or le Number of Shares				
Repor	ting O	wners														
						R	elationship	s								
Reporting Owner Name / Address Direct			Director	· · · · · · · · · · · · · · · · · · ·												

## **Signatures**

LARSON BRENT L

DUBLIN, OH 43017-7550

/s/William J. Kelly, attorney in fact	11/04/2015
**Signature of Reporting Person	Date

# **Explanation of Responses:**

5600 BLAZER PARKWAY, SUITE 200

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

10% Owner

(1) Sales effected pursuant to a 10b5-1 trading plan adopted by Mr. Larson on March 13, 2015.

Director

(2) Weighted average of sales prices ranging from \$1.95 to \$2.01 per share. Mr. Larson undertakes to provide upon request by the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Officer

EVP, CFO, Treas & Sec'y

Other

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.